Navigation Links
Onyx Pharmaceuticals Presents Carfilzomib Data at 53rd American Society of Hematology Annual Meeting
Date:12/12/2011

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced final results from a Phase 2 study, known as the 004 study, evaluating single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma. Results on prolonged infusion of carfilzomib and speed of response were also announced. These data were presented at the 53rd American Society of Hematology (ASH) Annual Meeting in San Diego, CA.

Abstract #813: Final Results from the Bortezomib-Naive Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma
Results from the 004 Phase 2 study evaluated single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who had received one to three prior treatments and had not been previously treated with bortezomib. In 67 evaluable patients, carfilzomib achieved an overall response rate (ORR) of 52 percent and a clinical benefit rate (CBR) of 64 percent when administered at 27mg/m(2). Sixty-four percent of patients were refractory to their most recent therapy prior to entering the trial. Overall response is defined as a partial response or greater.[i]  The median time-to-progression (TTP), duration of response (DOR) and overall survival (OS) were not reached in this study, designed to provide patients with up to 12 cycles of carfilzomib.  Forty-two percent of patients completed greater than 10 cycles and 22 patients continued treatment beyond one year in the extension protocol PX-171-010.

"This Phase 2 study demonstrates promising single-agent activity of carfilzomib in patients with relapsed and/or refractory multiple myeloma who have not been previously treated with bortezomib," said Ravi Vij, M.D., Associate Professor, Department of Medicine,
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Medina Medical announced ... and member of the Board of Directors on August ... device development and commercialization experience, including over a decade ... previously served as a Partner of the medical device ... CEO of two Foundry start-ups. Mr. Engelson previously served ...
(Date:8/29/2014)... 2014 Research and Markets has ... Therapeutics Market & Pipeline Insight 2014" report to ... to prevent and eradicate the prevalence of cancer have ... confined to low specificity, safety and large number of ... a better solution. It has been discovered that peptides ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Research and Development Trend Forecast of Pharmaceutical Equipment ... Research and Development Trend Forecast of ... 2014-2018 mainly analyzes China,s pharmaceutical ... supply & demand, competition landscape, and business performance of ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
... UBM Live today announced details of the ... pharmaceutical contract services and outsourcing. ICSE, hosted from June ... the most international pharmaceutical events line-up in China, which ... pharma machinery and equipment, BioPh China for the biopharmaceuticals ...
... Stereotaxis, Inc. (NASDAQ: STXS ) today ... 31, 2011.  First quarter results included continued strong momentum ... Odyssey™ systems and growth in recurring revenue.  In addition, ... which enhances the efficiency and versatility of the Niobe ...
Cached Medicine Technology:ICSE China to Offer Inaugural Conference Programme in 2011 2ICSE China to Offer Inaugural Conference Programme in 2011 3Stereotaxis Reports First Quarter 2011 Financial Results 2Stereotaxis Reports First Quarter 2011 Financial Results 3Stereotaxis Reports First Quarter 2011 Financial Results 4Stereotaxis Reports First Quarter 2011 Financial Results 5Stereotaxis Reports First Quarter 2011 Financial Results 6Stereotaxis Reports First Quarter 2011 Financial Results 7
(Date:9/1/2014)... September 02, 2014 NAPW ... Healthcare, LLC as a 2014 Professional Woman of the ... for leadership in office management. As the largest, most-recognized ... virtually every industry and profession, the National Association of ... over 600,000 members and nearly 300 Local Chapters. , ...
(Date:9/1/2014)... NAPW honors ... Orthopedics Pain Treatment & Cardiology, as a ... is recognized with this prestigious distinction for leadership ... organization of women in the country, spanning virtually ... Professional Women is a powerfully vibrant networking community ...
(Date:9/1/2014)... (PRWEB) September 02, 2014 Spine Team ... annual Reader’s Choice ‘Best of 2014’ award based on ... Northeast Tarrant County, Las Colinas & Coppell, Rockwall & ... would like to thank our patients and the residents ... Texas as LIVING magazine’s ‘Best of 2014’ in the ...
(Date:9/1/2014)... an innovative Washington State University study of deadly force ... black people. But when it came time to shoot, ... longer to pull the trigger against them than against ... the recent Journal of Experimental Criminology , grow ... disproportionate number of ethnic and racial minorities shot by ...
(Date:9/1/2014)... UWDress.com, a well-known wedding dress manufacturer and ... green bridesmaid dresses for its new and old ... company’s online category. What’s more, they are offered at ... offer is specially launched to celebrate the coming of ... have won great appreciation from worldwide clients. Now, the ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Announces Victoria Smith, Office Manager at Apex Healthcare, LLC, a 2014 Professional Woman of the Year 2Health News:National Association of Professional Women Announces Laura Brinkley, Manager, Gibson Orthopedics Pain Treatment & Cardiology Clinic, a 2014 Professional Woman of the Year 2Health News:Spine Team Texas chosen in LIVING Magazine’s Reader’s Choice Awards 2Health News:WSU 'deadly force' lab finds racial disparities in shootings 2Health News:WSU 'deadly force' lab finds racial disparities in shootings 3Health News:2014 Lime Green Bridesmaid Dresses Offered At UWDress.com 2
... could help keep ones mind working.The study also found those ... fat have an increased risk of cognitive impairment during middle ... eat could play a role in your risk for dementia. ... with a lower risk of dementia. Researchers in the Netherlands ...
... in the recent issue of British Medical Journal say ... suicides and suicidal attempts.// ,Depression is characterized ... activities, low levels of self-esteem and confidence, and in ... and suicide. ,Clinical depression, also known as ...
... thyroid problem may have a lower risk of developing ... have shown that one of the circulating thyroid hormones ... mammary gland cells responded to thyroid hormones , population ... thyroid hormone and breast cancer. ,In a recent ...
... recent study researchers suggest that women drink wine to keep their ... wine is good for the heart. Although much of the research ... men, it is still not clear why moderate amounts of wine ... effects of wine on women’s hearts, the alcohol habits of 102 ...
... research conducted by Northwestern University about the effects of epidural ... analgesic given at the early stages of labor does not ... in their final term were observed for the study. All ... women who were given epidural in the early stages of ...
... onset wheezing is associated with high levels of allergies, ... the longest duration of wheezing also appear to have ... later in childhood end up with the same characteristics ... involved nearly 1,500 children born on the Isle of ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: